Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $152.72 USD
Change Today -2.38 / -1.53%
Volume 1.4M
As of 8:04 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - $157.61
52 Week Low
07/29/14 - $84.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; minimally invasive continuous cardiac output monitoring systems and non invasive hemodynamic monitor for real time beat-to-beat information; pulmonary artery catheters; continuous venous oximetry catheter for measuring central venous oxygen saturation; and sensor-catheter sets that measures a critically ill patient's volumetric hemodynamic parameters. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

9,100 Employees
Last Reported Date: 02/20/15
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $758.8K
Corporate Vice President of EMEA, Canada and ...
Total Annual Compensation: $604.8K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $469.7K
Corporate Vice President of Transcatheter Hea...
Total Annual Compensation: $466.5K
Compensation as of Fiscal Year 2014.

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corp. Presents at Piper Jaffray Heartland Summit, Jun-23-2015

Edwards Lifesciences Corp. Presents at Piper Jaffray Heartland Summit, Jun-23-2015 . Venue: Minneapolis, Minnesota, United States. Speakers: Michael A. Mussallem, Chairman and Chief Executive Officer.

Edwards Receives FDA Approval for Sapien 3 Transcatheter Heart Valve

Edwards Lifesciences Corporation announced U.S. Food and Drug Administration (FDA) approval of its most advanced transcatheter aortic heart valve the Edwards SAPIEN 3 valve with the Commander Delivery System for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis. The PARTNER II study concluded that this new valve reduced several complications associated with the TAVR procedure such as paravalvular leakage and stroke, and represented a meaningful improvement over data from prior studies with earlier-generation devices. SAPIEN 3 approval was based on a cohort of the PARTNER II Trial, which enrolled 583 high-risk patients at 29 U.S. sites. The SAPIEN 3 valve builds on Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve, available in 20mm, 23mm, 26mm and 29mm sizes, has an outer skirt a cuff of fabric surrounding the valve frame providing a seal to address paravalvular leak.

Edwards Lifesciences Corporation Announces Encouraging Results from Aortic Stenosis Study

Edwards Lifesciences Corporation has announced that patients with aortic stenosis who received Edwards SAPIEN 3 transcatheter aortic valve via transfemoral delivery had a one-year survival rate of 91.6%, as well as low rates of stroke and paravalvular leak. The independently adjudicated data from the CE Mark study were presented. Among the outcomes reported from the study, transfemoral SAPIEN 3 transcatheter aortic valve replacement (TAVR) was associated with a disabling stroke rate of 1.1%. In addition, only 2% of patients had moderate paravalvular leaks and there were no reports of severe leaks. There were also no observations of structural valve deterioration. "The one-year survival rate in the transfemoral cohort is the high reported in a multicenter, fully adjudicated TAVR study to date. These results set a new standard of care for patients at high risk for surgical aortic valve replacement. The results of the SAPIEN 3 trial via the transfemoral approach also raise the question of whether transcatheter valve replacement should be considered for approval for all elderly patients with severe aortic stenosis’. The SAPIEN 3 Trial is a prospective, multicenter, non-randomized study. The one-year analysis documented outcomes of the first 150 patients treated with the SAPIEN 3 valve between Jan. 2013 and Nov. 2013 at 16 centers in Europe and Canada. Access approaches included transfemoral (n=96) and transapical/transaortic (n=54), as determined by the Heart Team. At baseline, the patients in the alternative access group were significantly sicker than the transfemoral group. All-cause mortality in the alternative access group was reported as 24.3% in the as-treated population. The SAPIEN 3 Trial is designed to evaluate patients annually for five years. The SAPIEN 3 valve can be delivered through a low-profile 14 French expandable sheath (eSheath). It also has an outer skirt - a cuff of fabric that provides a seal at the bottom of the frame that is designed to reduce paravalvular aortic regurgitation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $152.72 USD -2.38

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $190.14 USD +2.39
Endo International PLC $85.81 USD +0.42
Hologic Inc $37.66 USD -0.25
Intuitive Surgical Inc $544.15 USD -1.93
Mettler-Toledo International Inc $329.57 USD -6.16
View Industry Companies

Industry Analysis


Industry Average

Valuation EW Industry Range
Price/Earnings 19.3x
Price/Sales 7.0x
Price/Book 7.5x
Price/Cash Flow 19.1x
TEV/Sales 6.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at